Figure 1From: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsDistribution of ruxolitinib daily dose over the 24-week study period. N values represent patients with available dose information at the time of data analysis. Data shown for each time point represent the dose (in milligrams) that patients were receiving during the previous 4 weeks. BID, twice daily; QD, once daily.Back to article page